All In Biotech

Drug Trial Radar · NCT07220759

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

May 12, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

Conditions

  • Overweight
  • Obesity
  • Type 2 Diabetes

Interventions

  • CagrilintideDrug

    Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

  • Placebo (matched to Cagrilintide)Drug

    Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 64)

Locations

67 sites in 11 countries. Site status is shown where the registry gives one.

  • Univ of Alabama_Birmingham

    Birmingham, Alabama

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama

  • Noble Clinical Research

    Tucson, Arizona

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Headlands Research CTR Lincoln

    Lincoln, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Walgreens - Store 4442

    Kissimmee, Florida

  • Optimal Research Sites

    Orange City, Florida

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • East West Med Res Inst

    Honolulu, Hawaii

  • MediSphere Medical RC

    Evansville, Indiana

  • Walgreens - Store 3915

    Las Vegas, Nevada

  • Chear Center LLC

    The Bronx, New York

  • Centricity Res New Bern Multispeciality

    New Bern, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Holston Medical Group_Bristol

    Bristol, Tennessee

  • Velocity Clinical Res-Dallas

    Dallas, Texas

  • TPMG Clinical Research

    Newport News, Virginia

  • National Clin Res Inc.

    Richmond, Virginia

  • Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli

    Buenos Aires, Argentina

  • Buenos Aires Mácula

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • CICEMO- Consultorio de Investigación Clínica EMO

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • OCT Research ULC (dba Okanagan Clinical Trials)

    Kelowna, British Columbia, Canada

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, Canada

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, Canada

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, Canada

  • Hamilton Medical Research Group

    Hamilton, Ontario, Canada

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, Canada

  • Milestone Research

    London, Ontario, Canada

  • Centricity Res Pointe-Claire

    Pointe-Claire, Quebec, Canada

  • Diex Recherche Victoriaville

    Victoriaville, Quebec, Canada

  • Opca bolnica Karlovac

    Karlovac, Croatia

  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

    Krapinske Toplice, Croatia

  • Poliklinika SLAVONIJA OSIJEK

    Osijek, Croatia

  • Poliklinika Solmed

    Zagreb, Croatia

  • Lékařský dům Géčko

    České Budějovice, Czechia

  • Milan Kvapil s.r.o.

    Prague, Czechia

  • EUC Klinika Praha a.s.

    Prague, Czechia

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.